Wave Life Sciences (WVE) Free Cash Flow (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Free Cash Flow data on file, last reported at -$54.5 million in Q2 2026.

• Quarterly Free Cash Flow fell 17.59% year-over-year to -$54.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$193.1 million (up 3.48% YoY) and the FY2025 annual result came in at -$188.2 million, down 23.85% from the prior year.
• Free Cash Flow rose to -$54.5 million in Q2 2026, from -$60.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $85.0 million in Q1 2023 to a low of -$63.2 million in Q1 2025.
• A 5-year average of -$33.6 million and a median of -$36.0 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 377.36% — and 2023, when it surged 312.15%.
• Tracing WVE's Free Cash Flow over 5 years: stood at -$33.6 million in 2022, then advanced by 0.15% to -$33.6 million in 2023, then tumbled by 30.18% to -$43.7 million in 2024, then rose by 22.77% to -$33.8 million in 2025, then sank by 61.26% to -$54.5 million in 2026.
• The last three Free Cash Flow figures came in at -$54.5 million (Q2 2026), -$60.0 million (Q1 2026), and -$33.8 million (Q4 2025), per Business Quant data.